Major Depressive Disorder

Is it prolonged grief or MDD? Expert shares insights at premiere annual meeting.

Inaugural recipients will use funds to support infrastructure, student mental health, and programs for children with behavioral challenges.

The SSRIs’ mechanism of action is no index of safety and efficacy.

What are the biggest challenges facing both clinicians and patients, and how can we address them?

A psychiatrist lists the top 8 most pressing issues in MDD, from training to accessibility.

Does a computational approach to the mind pave the way for practicing a biopsychosocial psychiatry?

How can a greater emphasis on valued experiences both promote well-being and alleviate stress in patients?

The American Foundation for Suicide Prevention collaborates with Most Days, a mental health app, to provide suicide prevention expertise and content. Learn more about the partnership here.

Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.

Home environments have a clear impact on depression treatment outcomes.

In this CME, review novel, currently available, and promising pharmacological treatment options for treatment-resistant depression.

Zuranolone, a drug for the treatment of major depressive disorder and postpartum disorder, is on a rolling submission of a new drug application.

Sidney Zisook, MD, lists these as the top 8 issues in MDD.

In this CME, evaluate the treatment options for depression among older adults.

Study supports evidence for long-term impairment in memory, executive function.

Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.

In this CME article, learn about the best ways to assess depression in the geriatric population.

Results are clinically significant for the treatment of patients with major depressive disorder.

Are lower vitamin D levels in women related to depressive mood?

Investigators have launched a 3-year study to develop predictive models that will help identify better treatment plans for patients with depression.

If approved, this will be the fourth indication for the drug, joining its approvals for episodes associated with bipolar I disorder and schizophrenia.

A new study showed zuranolone treatment in patients with major depressive disorder demonstrates a rapid and statistically significant reduction in depressive symptoms.

Study also suggests link between postpartum depression and insomnia.

Data from a clinical program evaluating the efficacy and safety of zuranolone was presented at the American College of Neuropsychopharmacology Congress. What new developments did they share?

Research also shows increased prevalence of social risks and unmet social needs.